US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
イギリス
LSE
Archos (0OI0) 銘柄情報

Archos (0OI0)

0.784

0.00

(0.00%)

終了 7月9日 12:30AM

Archos (0OI0) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

0.784

( - )

買値

0.784

売値

0.784

出来高

677

平均取引量 (3 か月)

252,129 €

財務取引量

-

0.00 日の範囲 0.00

0.784 52 週間の範囲 0.784

時価総額

企業価値

16.212M

前日終値

0.784

始値

-

時刻

最終取引時間

VWAP

-

歳入

47.91M

純利益

744k

発行済株式数

58,053,021

浮動株比率 (%)

-

機関投資家保有比率 (%)

-

配当利回り

PER

15.25

株価売上高倍率 (PSR)

0.24

1 株当たり利益 (EPS)

0.01

ベータ

2.09

Archos S.A. manufactures and sells consumer electronics in France. The company offers tablets, bundles, and other accessories, as well as provides yoko solutions. Archos S.A. was founded in 1988 and is based in Igny, France. Archos S.A. manufactures and sells consumer electronics in France. The company offers tablets, bundles, and other accessories, as well as provides yoko solutions. Archos S.A. was founded in 1988 and is based in Igny, France.

セクター

-

業界

-

ウェブサイト

www.archos.com

本社

Igny, France

設立

1988

Archos is listed in the sector of the ロンドン証券取引所 with ticker 0OI0. The last closing price for Archos was 0.78 €. Over the last year, Archos shares have traded in a share price range of 0.784 € to 0.784 €.

Archos currently has 58,053,021 shares in issue. The market capitalisation of Archos is 45.51 € million. Archos has a price to earnings ratio (PE ratio) of 15.25.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0.784	0.784	0.784	693	0.784	DE
52	0	0	0.784	0.784	0.784	890	0.784	DE
156	0	0	0.784	313.6	0.784	7719	131.09135016	DE
260	0	0	0.784	313.6	0.784	8229	71.3018044	DE

0OI0 - Frequently Asked Questions (FAQ)

What is the current Archos share price?

The current share price of Archos is 0.784 €

How many Archos shares are in issue?

Archos has 58,053,021 shares in issue

What is the market cap of Archos?

The market capitalisation of Archos is EUR 45.51M

What is the 1 year trading range for Archos share price?

Archos has traded in the range of 0.784 € to 0.784 € during the past year

What is the PE ratio of Archos?

The price to earnings ratio of Archos is 15.25

What is the cash to sales ratio of Archos?

The cash to sales ratio of Archos is 0.24

What is the registered address of Archos?

The registered address for Archos is 3, rue AmpEre, Igny, Ile-de-France, 91430

What is the Archos website address?

The website address for Archos is www.archos.com

WizardlyRogue35

WizardlyRogue35 12分前

Do I Need SEC Compliance to Build a Crypto Exchange in the US?

Yes, but 2026 is actually the best time to build. SEC's Regulation Crypto introduces a four-year registration exemption for startups, allowing founders to raise up to $75 million without full securities registration. Bitde

bb8675309

bb8675309 25分前

Obama care destroyed our heath care in the United States of America. It was done on purpose. They hate America. Just like they hate Blarcamesine. You cannot take over a world super power externally. You do it internally by keeping the people sick. Imo.

sunspotter

sunspotter 26分前

“ there are only a few employees that receive a small salary. Others are paid in shares”

Please remind me exactly what valuable functions Kevin Bryan Williams - or any other “employee”* - performs for VPLM, a company that has no commercial activities or product of any kind, unless you

nowwhat2

nowwhat2 27分前

https://finance.biggo.com/news/d7d5c43e-0058-426d-8a43-8c936c9bbdbc

Yikes
https://www.google.com/search?q=does+spacex+have+a+larger+market+cap+than+bitcoin+%3F&sca_esv=42eda9f41fdefc69&sxsrf=APpeQnvfky8TDChr-SnuZGdpHdI9-v5wOA%3A1783474289068&source=hp&ei=cahNaorIAZnw0PEP2_OW6

nowwhat2

nowwhat2 33分前

Sound familiar ?
https://finance.biggo.com/podcast/009cfad6d4a6c602

Position, navigation, and timing (PNT) – startups like Mesa Quantum have shrunk the form factor from a coffee mug to a poker chip to a blueberry. These sensors measure local magnetic fields and can provide GPS-

axelvento

axelvento 34分前

Overweight Recommendation Issued On IMRX By Cantor Fitzgerald

https://marketwirenews.com/stock/imrx/news/overweight-recommendation-issued-on-imrx-by-cantor-f-8737586180020191.html?utm_source=rss-twitter

newflow

newflow 40分前

RALTA and LONG-FORM DSSOLUTION, WHAT IS IT ABOUT?.

chereb19

chereb19 47分前

Stop pretending you know every patient's clinical circumstances. "Non-resectable" does not mean "they have nothing to lose." That's your emotional spin, not the FDA's language or the trial protocol.

You're making the same mistake again—taking a medical term and rewriting it to fit you

chereb19

chereb19 49分前

Funny how you've gone from "they'll never get FDA authorization" to "it was only an EFS." The company has described the Early Feasibility pathway in its public filings for years. Pretending this was some last-minute downgrade is just rewriting history.

"Nothing to lose" isn't an FDA s

trender18

trender18 50分前

FITY looks like it's ready to breakout of this sideways trend very soon. https://www.barchart.com/stocks/quotes/FITY/technical-chart?plot=CANDLE&volume=total&data=DO&density=X&pricesOn=1&asPctChange=0&logscale=0&indicators=BBANDS(20,2);RSI(14,100);EXPMA(21);ACCUM;CHKMF(20);EXPMA(34);EXPMA(144)&sym=F

SC8

Stop posting nonsense. A person can live without a thyroid gland. Yes, at a minumum they'd be taking T4 daily for the remainer of their lives, but they can live and live well. The fact these thyroid cancers are non-resectable means they've spread beyond thyroid gland and are inoperable. They hav

William777

William777 54分前

Your words speak loudly. IMO what is coming will set records and reveal the truth about what can happen when greed by a few affect so many.

PickStocks

PickStocks 56分前

18 years and counting.. however RKt will be just fine

johnydollar

johnydollar 57分前

If we take responsibility of our lives we cut down the negative emotions..........

Say i am responsible......

And your anger will melt away like butter.......

https://youtube.com/shorts/TO1wEiA5IVk?is=LWZyrJQWyUPlAGbe

Slaytanic420

Slaytanic420 59分前

Brian and Alfonso are back at it

SC8

It wasn't an IDE application, but you already knew that. They were smart enough to summit an early feasibility application to treat a limited number of patients with nothing to lose, something they could have done decades ago.

Permapumpers morphing this approval into something it isn

lambchops

lambchops 1時間前

hope the chart proves it so!
Thanks for the reply CM!

LC

edgm

Truenorth2016

Truenorth2016 1時間前

BIEI Currently Under NDA Discussions For Aerospace Defense Coating Contracts Straight From PR!

"Premier is actively pursuing opportunities across graphene-enhanced defense composites, aerospace coatings, quantum-related materials research, and critical mineral resource in South Americ

Dr_Vonschellan

Dr_Vonschellan 1時間前

Deep Fission Prototype Reactor Canister Arrives at Kansas Site,
Advancing Reactor Proof-of-Concept Program
https://www.businesswire.com/news/home/20260707721954/en/Deep-Fission-Prototype-Reactor-Canister-Arrives-at-Kansas-Site-Advancing-Reactor-Proof-of-Concept-Program

W

chuck1418

chuck1418 1時間前

you got it Aqua. this is a good and informative post. very hard to find this in the subs.

Dr_Vonschellan

Dr_Vonschellan 1時間前

Deep Fission rings July 7 NASDAQ closing Bell
https://www.nasdaq.com/videos/deep-fission-rings-nasdaq-stock-market-closing-bell
skip to 8:57 minutes

The Doctor

4u2nv2

4u2nv2 1時間前

Who is J Coleman 1512 that is the media contact behind the most fabulous MCIC news? Who is this guy?https://investorshub.advfn.com/uimage/uploads/2026/4/5/[mzgoScreen_Shot_2026-04-05_at_1.50.39_AM.png

4u2nv2

4u2nv2 1時間前

I found the media contact if you have any more questions.https://investorshub.advfn.com/uimage/uploads/2026/4/5/[mzgoScreen_Shot_2026-04-05_at_1.50.39_AM.png

Waynewayne

Waynewayne 1時間前

Money making machine!

4u2nv2

4u2nv2 1時間前

https://investorshub.advfn.com/uimage/uploads/2026/4/5/[mzgoScreen_Shot_2026-04-05_at_1.50.39_AM.png

Nbc Canadian Banks Ar Pl...

Public Company Management (ID)

OMX Stockholm Retail GI

Centuria Office REIT

Biomarin Pharmaceutical

Elevance Health

State Street SPDR S&P Ca...

Lucy Scientific Discovery

Aledade Share Class Leve...

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。